| Patients with TTP | |
| Demographics | |
| Age, y (IQR) | 45 (29-53) |
| Male, n (%) | 12 (40) |
| Laboratory features | |
| Platelets, ×109/L (IQR) | 13 (9-30) |
| Hemoglobin, g/L (IQR) | 73 (60-98) |
| LDH, IU/L (IQR) | 1348 (871-1715) |
| Presence of schistocytes, n (%) | 30 (100) |
| ADAMTS13 activity, % (IQR) | 5 (0-5) |
| Anti-ADAMTS13 IgG, IU/mL | 71 (51-112) |
| Clinical features | |
| Mortality, n (%) | 10 (33) |
| Control patients | |
| Demographics | |
| Age, y (IQR) | 54 (53-58) |
| Male, n (%) | 5 (50) |
| Neurologic disease | |
| Myasthenia gravis, n (%) | 8 (80) |
| Acute polyradiculoneuritis, n (%) | 2 (20) |
| Patients with TTP | |
| Demographics | |
| Age, y (IQR) | 45 (29-53) |
| Male, n (%) | 12 (40) |
| Laboratory features | |
| Platelets, ×109/L (IQR) | 13 (9-30) |
| Hemoglobin, g/L (IQR) | 73 (60-98) |
| LDH, IU/L (IQR) | 1348 (871-1715) |
| Presence of schistocytes, n (%) | 30 (100) |
| ADAMTS13 activity, % (IQR) | 5 (0-5) |
| Anti-ADAMTS13 IgG, IU/mL | 71 (51-112) |
| Clinical features | |
| Mortality, n (%) | 10 (33) |
| Control patients | |
| Demographics | |
| Age, y (IQR) | 54 (53-58) |
| Male, n (%) | 5 (50) |
| Neurologic disease | |
| Myasthenia gravis, n (%) | 8 (80) |
| Acute polyradiculoneuritis, n (%) | 2 (20) |
IgG, immunoglobulin G; IQR, interquartile range; LDH, lactate dehydrogenase.